BMY's FDA filing for mezigdomide in relapsed or refractory multiple myeloma marks another step in advancing its protein degrader pipeline.

zacks.com - 2026-07-14 10:56:35

Voluntary pricing deals reduce uncertainty for major drugmakers. Drug pricing pressure won't affect every pharmaceutical company equally.

fool.com - 2026-07-14 05:00:00

The U.S. Food and Drug Administration (FDA) on Monday accepted the new drug application for Bristol Myers Squibb & Co.'s (NYSE:BMY) investigational oral therapy mezigdomide in combination with carfilzomib and dexamethasone for relapsed or refractory multiple myeloma.

benzinga.com - 2026-07-13 14:00:36

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--U.S. FDA Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma.

businesswire.com - 2026-07-13 06:59:00

Retiring on dividends remains achievable for late starters by building a high-yield, quality portfolio targeting a 6% yield with safe, growing payouts. Dividend-focused strategies mitigate sequence of returns risk, enabling investors to live off income rather than depleting principal during market downturns. Examples like Enbridge Inc. (ENB), Omega Healthcare Investors, Inc. (OHI), and Bristol-Myers Squibb Company (BMY) illustrate our buy low, sell high, and get paid to wait principles, delivering strong returns and dividend growth.

seekingalpha.com - 2026-07-10 08:00:00

They may not remain cheap for too much longer.

fool.com - 2026-07-07 18:30:00

AbbVie is hitting its stride now that it has transitioned past Humira's patent expiration. Medtronic is a steady dividend payer with some intriguing upside in robotics-assisted surgery.

fool.com - 2026-07-07 10:45:00

Bristol Myers Squibb is generating more than enough earnings to cover its dividend right now. However, the company faces a daunting patent cliff.

fool.com - 2026-07-06 04:44:00

Bristol Myers Squibb remains a Strong Buy, supported by steady performance and undervaluation despite recent underperformance versus the benchmark. BMY boasts a 4.43% forward dividend yield, over 2.7x the sector median, with 36 years of uninterrupted payments and 18 years of consecutive growth. Recent double-beat earnings and consistent estimate beats since 2024 reinforce positive sentiment and justify a premium valuation.

seekingalpha.com - 2026-07-03 23:58:47

BMY's growth portfolio now comprises 54.1% of revenues and delivered +9% YoY growth in FQ1'26 against the legacy portfolio's slower erosion, supporting further upside to the currently conservative FY2026 guidance. Strategic partnerships with Jiangsu Hengrui, accretive M&As, and strong uptake of Opdivo Qvantig underpin the company's multi-pronged portfolio renewal efforts, despite the near-term IPRD noise. BMY's intermediate-term top/bottom-line growth prospects are likely to underwhelm due to LOE risks from Eliquis/Opdivo, albeit with secure dividend payouts at 39.2% of free cash flow.

seekingalpha.com - 2026-07-03 09:25:00

Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

zacks.com - 2026-07-01 10:01:13

Bristol Myers Squibb focuses on specialized medicines in oncology and immunology, and shares sport a low valuation. Johnson & Johnson offers a diversified business model spanning innovative medicines and medical technology.

fool.com - 2026-07-01 07:30:01

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

zacks.com - 2026-06-30 10:41:22

A bipartisan group of United States lawmakers has opened national security investigations into whether five major pharmaceutical companies, including Merck...

proactiveinvestors.com - 2026-06-30 08:19:00

Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?

fool.com - 2026-06-30 07:45:03

In the latest trading session, Bristol Myers Squibb (BMY) closed at $58.56, marking a +1.81% move from the previous day.

zacks.com - 2026-06-29 18:46:11

At 66 with $1.3 million, the math is straightforward. A 5% blended yield throws off roughly $65,000 a year before Social Security. The cash flow underneath these three blue chips is what matters most for a retiree. I dug into each dividend to see which ones a 66-year-old can actually rely on. Bristol Myers Squibb:... 66 With $1.3 Million. Here Are 3 Hidden Gems to Target

247wallst.com - 2026-06-29 10:51:03

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

zacks.com - 2026-06-29 10:50:27

Bristol Myers Squibb maintains a robust biopharmaceutical portfolio focused on high-stakes oncology and immunology treatments. Johnson & Johnson leverages its massive scale and diversified segments to deliver high net margins and strong cash flow.

fool.com - 2026-06-26 11:30:15

Technical indicators show encouraging signs for the three stocks.

barrons.com - 2026-06-25 00:26:00

The latest trading day saw Bristol Myers Squibb (BMY) settling at $55.53, representing a +1.52% change from its previous close.

zacks.com - 2026-06-23 18:46:14

Bristol Myers Squibb has a big revenue gap to fill, but it seems up to the challenge. Its robust dividend yield will pay investors handsomely to wait things out.

fool.com - 2026-06-22 14:53:00

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026.

businesswire.com - 2026-06-18 06:59:00

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Dividend.

businesswire.com - 2026-06-17 16:16:00

Elicio Therapeutics Inc. (NASDAQ:ELTX) stock is up on Wednesday as the company reported promising clinical observations regarding its ELI-002 7P treatment.

benzinga.com - 2026-06-17 12:43:03

In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.

forbes.com - 2026-06-17 12:30:08

#TheMorningFilter #PortfolioRebalance #StockInvesting These value stocks can balance portfolios heavy in growth stocks—and they're undervalued, too. Watch The Morning Filter: https://www.youtube.com/live/aZZpyIILz3E?si=2QmG7OPY-biqvACZ 00:00:00 Introduction 00:00:32 Bristol-Myers Squibb BMY 00:01:09 Clorox CLX 00:02:50 Lockheed Martin LMT Watch more from Morningstar: 2 Overpriced Stocks to Sell https://youtu.be/2cDEjYfOvKI?si=3eirkC5_eHvZVWzT Ignore the Noise: These 2 Undervalued Stocks Could Be Winners https://www.youtube.com/watch?v=J07j3bAG2_g 3 More Stocks to Buy After Earnings https://www.youtube.com/watch?v=wB9mWstXyuA&t=21s Follow Morningstar on social: Facebook: https://www.facebook.com/MorningstarInc/ X: https://x.com/MorningstarInc Instagram https://www.instagram.com/morningstarinc/?hl=en LinkedIn: https://www.linkedin.com/company/5161/

youtube.com - 2026-06-17 12:00:09

Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.

zacks.com - 2026-06-17 10:02:20

Converging forces are pushing rates higher in 2026. The Iran conflict closed the Strait of Hormuz, spiking crude oil prices and raising production and transport costs. This energy shock drove inflation higher, with the Consumer Price Index rising 3.8%, which was the sharpest increase in three years and well above the Federal Reserve's 2% target.... Interest Rates Are Going Higher: 4 High-Yield Passive Income Stocks Can Weather Any Storm

247wallst.com - 2026-06-17 08:48:39

Bristol Myers eyes growth from Camzyos as the FDA reviews its use in adolescents with obstructive HCM, expanding the drug's market reach.

zacks.com - 2026-06-16 15:21:17

These three healthcare leaders are slowly overcoming recent obstacles. They have strong dividend track records and the means to maintain healthy dividend growth.

fool.com - 2026-06-16 06:15:00

With the 10-Year Treasury yielding 4.48% and the Fed signaling more cuts ahead, income investors are hunting for yield that compounds.

247wallst.com - 2026-06-15 10:50:06

Bristol Myers Squibb's yield is well above the pharma average, and it has patent expirations on the horizon. The payout ratio isn't outlandishly high, and the company is financially strong, as it deals with pretty normal issues in the drug sector.

fool.com - 2026-06-13 18:15:00

BMY's growth portfolio now drives more than half of revenues, with strong gains from Reblozyl, Breyanzi and Cobenfy helping offset legacy drug declines.

zacks.com - 2026-06-12 14:20:31

Bristol Myers Squibb (BMY) closed at $56.87 in the latest trading session, marking a +2.28% move from the prior day.

zacks.com - 2026-06-11 18:46:19

Multiple patent cliffs raise concerns about whether Bristol Myers Squibb can maintain its dividend growth streak. $3.5 billion in anticipated annual cost savings could help the pharmaceutical company bolster its quarterly payouts.

fool.com - 2026-06-11 14:02:00

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

zacks.com - 2026-06-11 10:40:33

Japan's Takeda Pharmaceutical said on Thursday its experimental once-daily psoriasis pill, developed with the help of AI, outperformed Bristol Myers Squibb's approved ​drug Sotyktu in a late-stage head-to-head study.

reuters.com - 2026-06-11 07:03:31

Bristol-Myers Squibb Company (BMY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-06-09 21:42:10

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMY--Mariska Hargitay Partners with BMS for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease.

businesswire.com - 2026-06-08 06:59:00

In the latest trading session, Bristol Myers Squibb (BMY) closed at $57.27, marking a +1.18% move from the previous day.

zacks.com - 2026-06-05 18:46:12

What does this smart money investor see that the market is missing?

fool.com - 2026-06-05 14:00:00

Arcus Biosciences teams up with Bristol Myers Squibb to test casdatifan combinations in kidney cancer, expanding its ccRCC development strategy.

zacks.com - 2026-06-04 12:55:34

Durability, not yield, is the deciding factor.

fool.com - 2026-06-04 02:30:00

Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.

zacks.com - 2026-06-03 10:00:41

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”). Under the agreement, Arcus will supply casdatifan, the company's investigational small-molecule HIF-2a inhibitor, to be eval.

businesswire.com - 2026-06-03 08:00:00

Both are working hard to get around patent cliffs. One of them seems to have made more progress on that front.

fool.com - 2026-06-03 03:45:00

Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but diverge sharply on risk, cash flow, and valuation.

fool.com - 2026-06-02 17:12:15

Bristol Myers secured EU approval for Opdivo plus AVD in newly diagnosed advanced cHL and advanced Camzyos' label expansion review.

zacks.com - 2026-06-02 14:01:14

Bristol Myers Squibb offers a compelling buy-the-dip opportunity with a forward P/E of 8.7x and a 4.6% dividend yield. BMY's diversified growth portfolio posted 9% YoY sales expansion, offsetting legacy drug declines and demonstrating early-stage growth runway. Upcoming pivotal clinical readouts in H2 2026, including milvexian and Cobenfy, are set to define BMY's long-term growth trajectory.

seekingalpha.com - 2026-06-02 10:59:47